Sigilon Therapeutics to Present at the Needham Healthcare Conference
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Needham Healthcare Conference on April 14, 2022, at 8:45 a.m. EDT. The event will be accessible via a webcast on the company's investor website, with a replay available for 90 days. Sigilon focuses on developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, utilizing non-viral engineered cell-based therapies to address conditions like lysosomal diseases and diabetes.
- None.
- None.
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Healthcare Conference. The presentation will take place on Thursday, April 14, 2022 at 8:45 a.m. EDT.
A webcast of the presentation will be accessible through the investor section of the company’s website at www.sigilon.com, with a replay available for 90 days following the event.
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or other therapeutic molecules needed by patients living with chronic diseases such as lysosomal diseases and diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Investor Contact
Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837
Media Contact
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349
FAQ
What is the date and time of Sigilon Therapeutics' presentation at the Needham Healthcare Conference?
Who will present at the Needham Healthcare Conference for Sigilon Therapeutics?
How can I access the webcast of Sigilon Therapeutics' presentation?
What is the main focus of Sigilon Therapeutics' research?
What types of diseases does Sigilon Therapeutics target?
